Bausch + Lomb announced an agreement with Express Scripts to begin coverage of Vyzulta (latanoprostene bunod ophthalmic solution) .024%. Under the agreement, Vyzulta is covered under an access position on both the commercial Express Scripts National Preferred and Basic formularies, giving access to an additional 23 million people in the United States. Vyzulta, the first prostaglandin analog with one of its metabolites being nitric oxide (NO), is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.

"We are proud of this achievement as it signifies the health care community’s recognition of the benefit Vyzulta may offer glaucoma patients," Tracy Valorie, senior vice president and general manager, U.S. Pharmaceuticals and Surgical, Bausch + Lomb, said in a company news release. "Bausch + Lomb is committed to providing our customers and their patients innovative medicines for prevalent eye health conditions."